X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Cons.: Back on double-digit growth path - Views on News from Equitymaster
StockSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK Cons.: Back on double-digit growth path
Aug 25, 2011

GSK Consumer Healthcare Ltd has announced second quarter results of calendar year 2011(2QCY11) results. The company has reported a 22% YoY and 15.8% YoY growth in income and net profits respectively. Here is our analysis of the results.

Performance summary
  • Sales grew by 21.6% YoY after a tepid rise of 9.5% in the previous quarter. The robust performance was backed by brisk growth of 16% in offtake.
  • Operating (EBITDA) margins for the company contracted by 126 basis points due to higher cost of goods sold & advertisement expenses as percentage of sales.
  • Net profit grew by a modest 15.8% on account of a slower rise in operating income partially offset by rising other income and lower tax incidence.


Rs(m) 2QCY10 2QCY11 Change
Revenue 5,525 6,739 22.0%
Expenditure 4,480 5,548 23.9%
Operating profit (EBDITA) 1,045 1,190 13.9%
EBDITA margin (%) 18.9% 17.7%  
Other income 129 155 19.9%
Interest 9 6 -31.1%
Depreciation 93 113 21.9%
Profit before tax 1,073 1,226 14.3%
Extraordinary inc/(exp) - -  
Tax 358 398 11.3%
Profit after tax/(loss) 715 827 15.8%
Net profit margin (%) 12.9% 12.3%  
No. of shares (m) 42 42  
Diluted earnings per share (Rs)*   77.3  
Price to earnings ratio (x)*   30.1  
*trailing twelve months

What has driven performance in 2QCY11?
  • The company's sales grew by a robust 21.6% led by a 16% jump in volumes on a YoY basis. In its mainstay health food drinks (HFD) segment, Horlicks and Maltova brands registered sales growth of 21% YoY and 19% YoY, respectively. The growths were driven by 11-16% increase in volumes and price-hikes of around 5-8%. Robust double-digit growth in the biscuits and noodle categories saw the contribution share of non-HFD segment grow by 110 basis points YoY to 6.2% of sales during the quarter. Regionwise, the company clocked the fastest growth of 31% YoY in the north where the revenue share is a miniscule 6% as compared to a revenue share of 44% in the south. Even exports that form 11% of sales, surged by 57% YoY in 2QCY11.

  • The overall price hike of 6% in 2QCY11 was unable to plug inflation in input costs. Thus the cost of goods sold to sales ratio increased by 275 basis points YoY to 39.4%. Increased competition particularly in the malted beverages led to a 124 basis points YoY jump in the company's ad-spends to sales ratio. Consequently, the operating margins fell by 126 basis points YoY to 17.7%.

  • At the net level, a 20% YoY increase in other income, mainly from business auxillary commission and interest earnings, coupled with lower tax incidence eased off margin pressure to some extent. As a result the profitability was marginally down by 66 basis points YoY to 12.3% in 2QCY11.

Cost break-up
As a % of sales 2QCY10 2QCY11 Change in basis points
Cost of goods sold 36.7% 39.4% 275
Staff costs 10.7% 10.1% 57
Advertisement costs 13.6% 14.8% 124
Other expenditure 20.2% 18.0% -216

What to expect?

At a price of Rs 2,329, the stock is trading at 22.3 times our estimated CY13 earnings. The company returned to its 20% plus growth phase in 2QCY11 backed by continued dominance in HFD's (70% market share) despite rising competition, growing demand for the non-HFD's and rising exports. Growing share of HFD revenues from the northern markets, brisk growth in biscuit, noodles & toothpaste segments and higher exports to the overseas markets in Bangladesh & Middle-East are future growth drivers. But at current high valuations, we advice 'CAUTION' on this stock.

To Read the Full Story, Subscribe or Sign In


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK CONSUMER SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK GSK CONSUMER

  • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK CONSUMER - GODFREY PHILLIPS COMPARISON

COMPARE GSK CONSUMER WITH

MARKET STATS